Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).

Shubham Pant; Alexander I. Spira; Byoung Chul Cho; Sanjay Goel; Christopher J. Hoimes; Ajjai Shivaram Alva; Rama Balaraman; Todd Michael Bauer; Philip A. Lowry; Ryan C. Ramaekers; Robert D. Siegel; Theresa Louise Werner; Nizar M. Tannir; Demiana Faltaos; Diane Potvin; Saskia T.C. Neuteboom; James Christensen; Richard C. Chao; Christos Kyriakopoulos

doi:10.1200/JCO.2018.36.15_SUPPL.4568

Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).

Shubham Pant
, Alexander I. Spira
, Byoung Chul Cho
, Sanjay Goel
, Christopher J. Hoimes
, Ajjai Shivaram Alva
, Rama Balaraman
, Todd Michael Bauer
, Philip A. Lowry
, Ryan C. Ramaekers
, Robert D. Siegel
, Theresa Louise Werner
, Nizar M. Tannir
, Demiana Faltaos
, Diane Potvin
, Saskia T.C. Neuteboom
, James Christensen
, Richard C. Chao
, Christos Kyriakopoulos

University of Texas MD Anderson Cancer Center
Virginia Cancer Specialists, Fairfax, VA;
Severence Hospital, Seou, Republic of Korea;
Albert Einstein College of Medicine
University Hospitals of Cleveland
University of Michigan
Ocala Onc, Ocala, FL;
Sarah Cannon Research Institute
Guthrie Cancer Ctr, Sayre, PA;
CHI Health
Bon Secours St. Francis Health System, Greenville, SC;
University of Utah
Mirati Therapeutics, Inc., San Diego, CA;
University of Wisconsin-Madison

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	36
DOIs	https://doi.org/10.1200/JCO.2018.36.15_SUPPL.4568
State	Published - Jun 1 2018
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology

Access to Document

10.1200/JCO.2018.36.15_SUPPL.4568License: Unspecified

Cite this

Pant, S., Spira, A. I., Cho, B. C., Goel, S., Hoimes, C. J., Alva, A. S., Balaraman, R., Bauer, T. M., Lowry, P. A., Ramaekers, R. C., Siegel, R. D., Werner, T. L., Tannir, N. M., Faltaos, D., Potvin, D., Neuteboom, S. T. C., Christensen, J., Chao, R. C., & Kyriakopoulos, C. (2018). Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT). Journal of Clinical Oncology, 36. https://doi.org/10.1200/JCO.2018.36.15_SUPPL.4568

Pant, S, Spira, AI, Cho, BC, Goel, S, Hoimes, CJ, Alva, AS, Balaraman, R, Bauer, TM, Lowry, PA, Ramaekers, RC, Siegel, RD, Werner, TL, Tannir, NM, Faltaos, D, Potvin, D, Neuteboom, STC, Christensen, J, Chao, RC & Kyriakopoulos, C 2018, 'Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).', Journal of Clinical Oncology, vol. 36. https://doi.org/10.1200/JCO.2018.36.15_SUPPL.4568

@article{741af9ffde514b2ab9e0ebeaebd6a9e7,

title = "Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).",

author = "Shubham Pant and Spira, \{Alexander I.\} and Cho, \{Byoung Chul\} and Sanjay Goel and Hoimes, \{Christopher J.\} and Alva, \{Ajjai Shivaram\} and Rama Balaraman and Bauer, \{Todd Michael\} and Lowry, \{Philip A.\} and Ramaekers, \{Ryan C.\} and Siegel, \{Robert D.\} and Werner, \{Theresa Louise\} and Tannir, \{Nizar M.\} and Demiana Faltaos and Diane Potvin and Neuteboom, \{Saskia T.C.\} and James Christensen and Chao, \{Richard C.\} and Christos Kyriakopoulos",

note = "4568 Background: Sitravatinib (MGCD516) is an oral, potent small molecule inhibitor of a closely related spectrum of receptor tyrosine kinases (RTKs) including the TAM family (AXL, MER), split RTKs (VEGFR2, PDGFR, KIT), RET and MET.",

year = "2018",

month = jun,

day = "1",

doi = "10.1200/JCO.2018.36.15\_SUPPL.4568",

language = "American English",

volume = "36",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).

AU - Pant, Shubham

AU - Spira, Alexander I.

AU - Cho, Byoung Chul

AU - Goel, Sanjay

AU - Hoimes, Christopher J.

AU - Alva, Ajjai Shivaram

AU - Balaraman, Rama

AU - Bauer, Todd Michael

AU - Lowry, Philip A.

AU - Ramaekers, Ryan C.

AU - Siegel, Robert D.

AU - Werner, Theresa Louise

AU - Tannir, Nizar M.

AU - Faltaos, Demiana

AU - Potvin, Diane

AU - Neuteboom, Saskia T.C.

AU - Christensen, James

AU - Chao, Richard C.

AU - Kyriakopoulos, Christos

N1 - 4568 Background: Sitravatinib (MGCD516) is an oral, potent small molecule inhibitor of a closely related spectrum of receptor tyrosine kinases (RTKs) including the TAM family (AXL, MER), split RTKs (VEGFR2, PDGFR, KIT), RET and MET.

PY - 2018/6/1

Y1 - 2018/6/1

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.4568

U2 - 10.1200/JCO.2018.36.15_SUPPL.4568

DO - 10.1200/JCO.2018.36.15_SUPPL.4568

M3 - Article

VL - 36

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).

Disciplines

Access to Document

Other files and links

Cite this